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Despite extensive study, deﬁnitive conclusions regarding the relationship between asthma and consumer
products remain elusive. Uncertainties reﬂect the multi-faceted nature of asthma (i.e., contributions of
immunologic and non-immunologic mechanisms). Many substances used in consumer products are asso-
ciated with occupational asthma or asthma-like syndromes. However, risk assessment methods do not
adequately predict the potential for consumer product exposures to trigger asthma and related syn-
dromes under lower-level end-user conditions. A decision tree system is required to characterize asthma
and respiratory-related hazards associated with consumer products. A system can be built to incorporate
the best features of existing guidance, frameworks, and models using a weight-of-evidence (WoE)
approach. With this goal in mind, we have evaluated chemical hazard characterization methods for
asthma and asthma-like responses. Despite the wealth of information available, current hazard charac-
terization methods do not deﬁnitively identify whether a particular ingredient will cause or exacerbate
asthma, asthma-like responses, or sensitization of the respiratory tract at lower levels associated with
consumer product use. Effective use of hierarchical lines of evidence relies on consideration of the rele-
vance and potency of assays, organization of assays by mode of action, and better assay validation. It is
anticipated that the analysis of existing methods will support the development of a reﬁned WoE
approach.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Approximately 23 million persons in the United States of Amer-
ica, including children, are currently affected by asthma (American
Lung Association, 2010). Due, in part, to the increasing prevalence
of this disease, the possible relationship between asthma and
exposure to consumer products is gaining public attention and
increasingly becoming a research priority. Several reviews have
implied that the use of cleaning products in residential and com-
mercial applications may potentially induce or trigger asthma
(Jaakkola and Jaakkola, 2006; Nielsen et al., 2007; Quirce and
Barranco, 2010; Zock, 2005; Zock et al., 2010; Rosenman et al.,
2003). One response to this concern has been the publication oflists of substances that are known to, or are suspected of, causing
asthma (NIH, 2012; AOEC, 2008).
The efforts to better understand and prevent asthma-inducing
chemical exposures beneﬁt public health due to the signiﬁcant
impact these exposures have on the large number of affected
patients and potentially susceptible consumers. Asthma is gener-
ally deﬁned as a chronic inﬂammatory disease of the lung
(NHLBI, 2007), in which the airways narrow due to a combination
of smooth muscle contraction, inﬂammatory responses, mucosal
edema, and mucus in the lumen of the bronchi and bronchioles
(Lemanske and Busse, 2010; NHLBI, 2007). It commonly presents
with intermittent and reversible symptoms of cough, wheeze,
dyspnea (shortness of breath), and/or chest tightness (AOEC,
2008) and with wheezing heard on chest exam, and reversible air-
ﬂow obstruction found on pulmonary function tests. Asthma is a
clinical diagnosis but, due to variation in symptom presentation
and an absence of asthma-speciﬁc tests or biomarkers, it is often
difﬁcult to evaluate the link between speciﬁc exposures and
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evaluate relationships between exposure and asthma-like symp-
toms (e.g., cough, wheeze, and dyspnea), although such studies
are generally subject to a number of limitations.
Asthma is a complex disease with multiple potential mecha-
nisms of toxicity for both induction and aggravation of pre-existing
asthma (see Fig. 1). Asthma is associated with pulmonary inﬂam-
mation, and the mechanism of action (MOA) often, but not always,
involves adaptive immunity. This mechanism is generally associ-
ated with high- (HMW) or low-molecular-weight (LMW) chemi-
cals that trigger immune responses that are associated with the
appearance of IgE and IgE antibodies in the plasma. Occupational
asthma to chemicals is sometimes associated with a speciﬁc IgE
antibody. There has been some debate about the requirement for
IgE antibody in the pathogenesis of occupational asthma to chem-
icals. However, it has been hypothesized that the association
between occupational asthma and IgE antibody is somewhat closer
than has been claimed previously (Kimber and Dearman, 2002).
Nevertheless, with some chemicals, and in particular with the diis-
ocyanates, it has often proven difﬁcult to ﬁnd IgE antibody in the
serum of symptomatic patients and it might be that other immu-
nological processes are relevant (Mapp et al., 1994, 2005; Walker
et al., 1992). This potential pathway is unknown, and there is still
uncertainty whether sensitization (i.e., hyperresponsiveness) of
the respiratory tract can be achieved properly in the absence of
IgE. Moreover, it is important ro recognize that some chemicals
are associated with asthma responses in the absence of an immu-
nological response. Thus, for instance, a single exposure to high
concentrations of chemical irritants (e.g., hydrogen chloride) can
cause an asthma-like condition called reactive airways dysfunction
syndrome (RADS), which is non-immunologically mediated. RADS
symptoms occur within hours of the initial exposure and may con-
tinue as non-speciﬁc bronchial hyper-responsiveness for extended
durations (Bernstein, 1993). More recently, the hypothesis that low
level, longer-term exposure to irritants may also induce asthma or
an asthma-like syndrome called low-intensity chronic exposure
dysfunction syndrome (LICEDS) is gaining acceptance (Baur et al.,
2012). This complex mixture of biological mechanisms makes the
prediction and characterization of causal relationships between
exposure and asthma very challenging.
Thus, there is a need for further evaluation of environmental
exposures, especially those linked to household environments and
indoor air quality, and their possible association with asthma (ACI,
2012). To tackle this challenge in a systematic way, many organiza-Fig. 1. Asthma is a complex disease with multiple modes of action (MOA) that may o
unknown relationships. Clinical data are important for the diagnosis of asthma, but can a
primarily useful for determining the potential of a chemical to cause an immunologic re
asthma induction is plausible. Adapted from Bernstein et al. (2006).tions and agencies (e.g., European Union, World Health Organiza-
tion, Association of Occupational and Environmental Clinics) have
developed decision tools for assessing relationships between a spe-
ciﬁc chemical (or process) and asthma or asthma-like symptoms
(e.g., sensitization of the respiratory tract). None of these methods
is harmonized; each compiles and integrates diverse lines of evi-
dence from human health effects investigations or toxicology stud-
ies in different ways. Moreover, the intended uses and data analysis
criteria that support the numerous available hazard classiﬁcation
schemes vary widely, possibly due to a lack of accurate and speciﬁc
diagnostic and prognostic tools for asthma. Currently, there are no
fully validated animal, in vitro, or in silicomodels that have received
widespread acceptance for identifying whether a speciﬁc chemical
can cause asthma and/or sensitization of the respiratory tract.
From a risk and product safety assessment perspective, a meth-
odology to predict likely causation of asthma would be highly
useful, speciﬁcally a hazard characterization tool that is well-
developed and communicated. Determining risks of asthma is difﬁ-
cult since exposure scenarios for consumer products vary greatly
and dose–response estimation is complex due to uncertainties
about the underlying biology. Nonetheless, a hazard characteriza-
tion framework can be used to provide an informed approach for
risk management and for protecting against and limiting exposure
to chemicals thought to cause asthma. A signiﬁcant challenge for
developing a hazard characterization framework is creating a
highly integrated approach that considers both immunologic and
non-immunologic mechanisms of the induction of asthma, and
can accommodate the various types of studies and alternative lines
of evidence that might be available for such diverse toxicity
mechanisms.
In this manuscript, we review and critically evaluate multiple
hazard characterization frameworks and consider how in vivo,
in vitro, and in silico models can be used for characterizing asthma
hazards. The goal of this work is to identify the aspects of currently
available systems that are most effective for evaluating asthma
hazards, and/or effects that are related to the induction of asthma
(including, importantly, sensitization of the respiratory tract), with
the intent of building a novel, WoE-based hazard characterization
tool for determining asthma-speciﬁc risk.
2. Methods
We identiﬁed multiple hazard characterization frameworks and
guidelines that provide methods for evaluating and determiningr may not act independently of each other. Dashed arrows indicate probable, but
lso be used to gather sensitization and irritation information. Sensitization data are
action. Irritation data can be used to predict whether a non-immunologic MOA for
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symptoms, and/or respiratory sensitization. Our identiﬁcation
drew heavily from the NIH-sponsored report on asthma (NHLBI,
2007). Frameworks or guideline documents were excluded if they
did not: (1) consider asthma or sensitization of the respiratory
tract, (2) include multiple lines of evidence for evaluating the
potential to cause or exacerbate asthma, and/or (3) provide a deci-
sion method for identifying chemicals that may increase the risk of
asthma. By including only frameworks with a documented deci-
sion process or rationale, we have chosen not to include resources
from agencies or organizations that provide only a list of suspect
chemicals or substances. Many of these excluded resources were
originally considered for this project because they were cited in
the NIH-sponsored report on asthma and chemicals in consumer
products (NHLBI, 2007). The included frameworks were evaluated
by a panel of experts using a peer consultation approach.3. Results
3.1. Deﬁning asthma, and other related terms
The deﬁnition of asthma varies among organizations dealing
with public health and asthma-related research (Table 1). Although
there are different deﬁnitions for asthma, those proposed by each
organization reﬂect their intended context and purpose as used
by that organization (see Fig. 2). Thus, a single consensus deﬁnition
is not needed because what is most important is to clarify how one
deﬁnes asthma in the speciﬁc use context for each organization.
However, for risk and safety assessment tool development, deﬁn-
ing a common language to describe, recognize, and assess particu-
lar health effects would drastically reduce confusion and allow for
accurate and appropriate evaluation of hazard.
In addition to the lack of harmonization around the deﬁnition of
asthma, there are multiple other key terms related to asthma that
have many different implications and can cause confusion among
the scientiﬁc, medical, and lay communities (see Table 2). For the
purposes of this manuscript, it is important to note that sensitiza-
tion of the respiratory tract is not equivalent to asthma, although it
shares some symptoms and is likely related to asthma; asthma
may be one result of allergic sensitization of the respiratory tract,
but sensitization of the respiratory tract does not necessarily result
in asthma (i.e., about 40% of individuals with allergic rhinitis also
have asthma, and about 94% of patients with allergic asthma have
allergic rhinitis; Bergeron and Hamid, 2005). Overall, it is recom-
mended that precise language be used and terms be clearly deﬁned
for each application, while noting the value of ﬂexibility of needs
for communicating to different audiences.
3.2. Hazard characterization frameworks for evaluating asthma
A concise summary of ﬁndings from the analysis of frameworks
for evaluating asthma or asthma-like symptoms (e.g., sensitization
of the respiratory tract) is shown in Table 3; this highlights fea-
tures of the frameworks that are used for characterizing hazard.
Table 4 summarizes the endpoints that are evaluated within each
framework. Each framework is described in more detail in the fol-
lowing sections.
3.3. AOEC (Association of Occupational and Environmental Clinics)
The AOEC Exposure Code List is a list of chemicals with poten-
tial to cause and/or exacerbate asthma; it is intended to identify
substances that may cause de novo cases of asthma, not just
response elicitation, based on both the sensitizing and non-sensi-
tizing, or irritant (e.g., RADS), causes of asthma (Hunting andMcDonald, 1995). Of the large number of substances identiﬁed,
only approximately 60 substances were reviewed using the spe-
ciﬁc criteria established by AOEC (2008). The AOEC method uses
a WoE approach to determine possible causality; one positive
response is not sufﬁcient to associate a product or chemical with
asthma. However, it is limited by its focus on occupational expo-
sures. Many of the chemicals included in its analyses and lists
are also used within the home and/or by the general public. Due
to differences in exposure scenarios, workers may exhibit asth-
matic responses in relationship to occupational exposures of
chemicals that may not be relevant exposures for consumers.
Moreover, the approach does not take animal toxicology data into
consideration; instead, the AOEC approach was intended for
patient diagnosis and relies on human effects information. The
absence of animal data use limits the number of substances that
can meet the AOEC criteria since most chemicals lack clinical or
epidemiology studies.
3.4. TERA (Toxicology Excellence for Risk Assessment) (2014)
This framework considers three endpoints: asthma, respiratory
tract irritation, and sensitization of the respiratory tract. Each end-
point is assigned a category based on the likelihood that a chemical
causes that effect, which in turn is based on the WoE available. The
purpose of these categories is to prioritize chemicals by their like-
lihood to potentially cause and/or exacerbate asthma recognizing
the possibility that multiple toxic mechanisms might be relevant.
Data from standard, non-respiratory irritation protocols (e.g., skin,
ocular, and in vitro) are also evaluated. Respiratory sensitization is
categorized as either present or absent in this WoE approach
because there is no current consensus method for determining rel-
ative sensitizing potency. This approach also includes a data hier-
archy that accounts for test species, exposure route, study
quality, and endpoint relevance.
Depending on the outcome of the WoE evaluations for each
individual endpoint, a decision matrix is used to categorize the
likelihood that a chemical will cause and/or exacerbate asthma.
3.5. World health organization/international programme on chemical
safety
The WHO/IPCS approach provides guidelines for assessing
immune suppression, immunostimulation, sensitization and aller-
gic response, and autoimmunity and autoimmune disease. This
guidance recommends use of a WoE approach for determining
respiratory and skin sensitization and allergy risk (shown in Fig-
ures. 6.2 A and B of IPCS, 2012); this approach requires the pres-
ence of a dose–response relationship and biological plausibility
to determine causality. The framework is not, however, speciﬁc
to asthma. Human data are weighted more heavily than data from
animal studies, with clinical studies having a greater weight than
observational studies (e.g., cohort, case-control, and cross-sec-
tional studies); case-reports are considered supporting evidence.
3.6. Selgrade et al. (2012)
Selgrade et al. (2012) developed guidance for determining the
sensitizing potential of chemicals based on EC Regulation No.
1272/2008 Classiﬁcation, Labeling, and Packaging of Substances;
REACH guidance from the European Chemicals Agency; and the
United Nations Globally Harmonized System (GHS). Separate deci-
sion trees evaluate potential skin and respiratory sensitizers and
for individual exposures and mixtures (Figs. 1, 2 and 4, in
Selgrade et al., 2012). The guidance is speciﬁc for sensitization,
and does not address asthma that is not associated with immune
or allergic responses. Only key human studies can be used to
Table 1
Deﬁnitions of asthma gathered from multiple organizations.
Group Deﬁnition Website
The Association of Occupational &
Environmental Clinics (AOEC, 2008)
Asthma is a condition of variable airﬂow obstruction, commonly
presenting with symptoms of cough, wheeze, dyspnea, or chest tightness.
In most cases wheezing is heard in the chest during active episodes, but
wheezing may resolve completely between episodes. Asthma is a clinical
diagnosis since there is no single test, biomarker, or gene speciﬁc for
asthma
http://www.aoec.org
American Thoracic Society (ATS, 2010) Asthma is a common but complex disease of the pulmonary airways
(trachea, bronchi, and bronchioles) that is characterized by difﬁculties
getting air in and out of the lungs (variable airﬂow obstruction),
environmental triggers causing breathlessness (airway
hyperresponsiveness), and cellular inﬂammation
http://www.thoracic.org/education/breathing-
in-america/resources/chapter-3-asthma.pdf
British Thoracic Society (BTS) and
Scottish Intercollegiate Guidelines
Network (SIGN) (2009)
The diagnosis of asthma is a clinical one; there is no standardized
deﬁnition of the type, severity, or frequency of symptoms, nor of the
ﬁndings on investigation. The absence of a gold standard deﬁnition means
that it is not possible to make clear evidence based recommendations on
how to make a diagnosis of asthma. Central to all deﬁnitions is the
presence of symptoms (more than one of wheeze, breathlessness, chest
tightness, cough) and of variable airﬂow obstruction. More recent
descriptions of asthma in children and in adults have included airway
hyper-responsiveness and airway inﬂammation as components of the
disease. How these features relate to each other, how they are best
measured, and how they contribute to the clinical manifestations of
asthma, remains unclear. Although there are many shared features in the
diagnosis of asthma in children and in adults, there are also important
differences. The differential diagnosis, the natural history of wheezing
illnesses, the ability to perform certain investigations and their diagnostic
value, are all inﬂuenced by age. Asthma in children causes recurrent
respiratory symptoms of: wheezing, cough, difﬁculty breathing, and chest
tightness. Clinical features in adults that inﬂuence the probability that
episodic respiratory symptoms are due to asthma include: (1) More than
one of the following symptoms: wheeze, breathlessness, chest tightness
and cough, particularly if: symptoms worse at night and in the early
morning; symptoms in response to exercise, allergen exposure and cold
air; and symptoms after taking aspirin or beta blockers; (2) History of
atopic disorder; (3) Family history of asthma and/or atopic disorder; (4)
Widespread wheeze heard on auscultation of the chest; (5) Otherwise
unexplained low FEV1 or PEF (historical or serial readings); and (6) f
Otherwise unexplained peripheral blood eosinophilia
http://www.brit-thoracic.org.uk/Portals/0/
Guidelines/AsthmaGuidelines/
sign101%20revised%20June%2009.pdf
US Centers for Disease Control and
Prevention
Asthma is a chronic disease that affects the airways in the lungs. During an
asthma attack, airways become inﬂamed, making it hard to breathe.
Asthma attacks can be mild, moderate, or serious — and even life
threatening
http://www.cdc.gov/asthma/impacts_nation/
AsthmaFactSheet.pdf
US Environmental Protection Agency
(2010)
Asthma is a chronic inﬂammatory disorder of the airways, designated as
ICD9-CM-493 in the International Classiﬁcation of Diseases (ICD-9).
Airway inﬂammation contributes to airway hyperresponsiveness, airﬂow
limitation, respiratory symptoms, and the chronic nature of the disease.
Airﬂow limitation and the narrowing of airways can be manifested as
acute bronchoconstriction, airway edema, mucus plug formation, and
remodeling of the airway walls. In susceptible individuals, this
inﬂammation causes recurrent episodes of wheezing, breathlessness,
chest tightness, and coughing. Asthma patients are usually categorized as
having mild persistent, mild intermittent, moderate persistent, or severe
persistent asthma, based on symptoms and the results of diagnostic tests
http://www.epa.gov/opptintr/coi/pubs/
iv_2.pdf
European Union (EU) (2013) The EU deﬁnes asthma as an allergic reaction to substances commonly
breathed in through the air, such as animal dander, pollen, or dust mite
and cockroach waste products. The catch-all name for these substances,
allergens, refers to anything that provokes an allergic reaction. Some
people have a genetic predisposition to react to certain allergens. When
these people breathe in the allergen, the immune system goes into high
gear as if ﬁghting off a harmful parasite. The system produces a molecule
called immunoglobulin E (IgE), one of a class of defensive molecules
termed antibodies. The IgE antibody is central to the allergic reaction. For
example, it causes mast cells, a type of specialized defensive cell, to
release chemical ‘‘weapons’’ into the airways. The airways then become
inﬂamed and constricted, leading to coughing, wheezing, and difﬁculty
breathing – an asthma attack (deﬁnition provided by the US National
Institute of Allergy and Infectious Diseases)
http://ec.europa.eu/health/
major_chronic_diseases/diseases/asthma/
index_en.htm
Mayo Clinic Staff (2012) Asthma is a condition in which your airways narrow and swell and
produce extra mucus. This can make breathing difﬁcult and trigger
coughing, wheezing and shortness of breath. For some people, asthma is a
minor nuisance. For others, it can be a major problem that interferes with
daily activities and may lead to a life-threatening asthma attack. Asthma
can’t be cured, but its symptoms can be controlled. Because asthma often
changes over time, it’s important that you work with your doctor to track
your signs and symptoms and adjust treatment as needed
http://www.mayoclinic.com/health/asthma/
DS00021
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Table 1 (continued)
Group Deﬁnition Website
National Library of Medicine (2013) Asthma is a disorder that causes the airways of the lungs to swell and
narrow, leading to wheezing, shortness of breath, chest tightness, and
coughing. Asthma is caused by inﬂammation in the airways. When an
asthma attack occurs, the muscles surrounding the airways become tight
and the lining of the air passages swells. This reduces the amount of air
that can pass by. In sensitive people, asthma symptoms can be triggered
by breathing in allergy-causing substances (called allergens or triggers)
http://www.ncbi.nlm.nih.gov/pubmedhealth/
PMH0001196/
Selgrade et al. (2006) ‘‘Dealing with asthma means many different things to different people. To
the patient, it means episodic wheezing, coughing, and/or shortness of
breath. To the parent, it may mean sleepless nights or missed workdays
because of the presence of symptoms in their child. To the clinician,
asthma is a complex condition that presents as multiple different
phenotypes that can vary with age, gender, and race. Moreover, the
frequency and severity of asthma ‘‘attacks’’ may have both inter- and
intrapatient variability and can be triggered by diverse stimuli including
aeroallergen exposure, viral infections, exercise, irritant exposure, certain
medications (e.g., aspirin), and gastroesophageal reﬂux. To the
pathologist, asthma is characterized by airway inﬂammation and mucus
hypersecretion. To the physiologist, airﬂow obstruction and airway
hyperresponsiveness are most relevant’’
http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC1440790/pdf/ehp0114–000615.pdf
National Heart Lung and Blood Institute
(2007)
Asthma is a common chronic disorder of the airways that is complex and
characterized by variable and recurring symptoms, airﬂow obstruction,
bronchial hyperresponsiveness, and an underlying inﬂammation. The
interaction of these features of asthma determines the clinical
manifestations and severity of asthma and the response to treatment
http://www.nhlbi.nih.gov/guidelines/asthma/
asthgdln.pdf
World Health Organization (2013) Asthma attacks all age groups but often starts in childhood. It is a disease
characterized by recurrent attacks of breathlessness and wheezing, which
vary in severity and frequency from person to person. In an individual,
they may occur from hour to hour and day to day. This condition is due to
inﬂammation of the air passages in the lungs and affects the sensitivity of
the nerve endings in the airways so they become easily irritated. In an
attack, the lining of the passages swell causing the airways to narrow and
reducing the ﬂow of air in and out of the lungs
http://www.who.int/respiratory/asthma/
deﬁnition/en/
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WoE argument. The guidance describes how to determine whether
human data are of sufﬁcient quality to support classiﬁcation as a
sensitizer. If good quality human data are not available, weaker
human data, data from animal studies, and structure activity rela-
tionships may all be used to build a WoE assessment.3.6. Globally harmonized system
GHS is used and incorporated into the hazard characterization
approaches of many international organizations and regulatory
agencies. This system provides a clear approach for determining
both respiratory sensitization and irritation, relying heavily on a
WoE approach. Data types are clearly prioritized and there are
requirements for meeting a minimum standard for determining
causality. Immunological mechanisms do not have to be evident
in order to assign a respiratory sensitizer classiﬁcation. However,
this approach does not assess asthma, speciﬁcally, and instead
allows investigators to make an assumption on the potential of a
substance to cause and/or exacerbate asthma based on respiratory
sensitization and irritation alone.3.7. Critical review of the multiple frameworks on asthma hazard
characterization
A summary of the advantages and disadvantages from each
framework is shown in Table 5. There is no single, currently-exist-
ing framework that can be directly adopted or readily modiﬁed for
effectively characterizing the asthma hazard of substances with an
unknown potential for causing asthma. Rather, different features of
multiple frameworks could be combined to create an improved
approach with additional reﬁnement.4. Discussion
We analyzed the landscape of methods used to assess and com-
municate potential hazards related to asthma responses and chem-
ical exposures. The analysis centered on a critical examination of
existing hazard characterization methods. Although none of the
methods cover all aspects of asthma response, highlighting ele-
ments of existing methods clariﬁes the intent of the individual
methods and enables informed safety assessment decisions. One
clear ﬁnding from our analysis is that a highly-predictive model
for asthma hazard characterization needs to be nimble to account
for the complexities of the asthma response. Key features of a
robust approach for evaluating asthma safety include: a clear
description of the scope and purpose of the assessment, consider-
ation of exposure (extent, duration, and pertinent routes) and rel-
evance to consumer product scenarios, a nuanced approach to the
mode of action testing for asthma induction and elicitation (e.g.,
allergic versus non-allergic asthma), and a well-documented WoE
process to organize data in a hierarchical manner (Fig. 3).
Two key elements of this overall framework that are particu-
larly complex for hazard characterization of asthma are deﬁning
the mode of action (MOA) (because of the biological complexity
of asthma) and developing a rigorous WoE approach (because of
limitations in data, assays, and predictive models).
The complication of an MOA-centered approach is of special
importance for asthma, as no single assay can identify with cer-
tainty the potential of a chemical to induce asthma or verify the
original cause of asthma once it has developed. Even if we limit a
hazard characterization method to a speciﬁc MOA (e.g., sensitiza-
tion of the respiratory tract), it is difﬁcult to identify the deﬁning
characteristics of the chemicals that cause symptoms related to
asthma. To the degree that the MOA hypothesis can be narrowed,
the overall WoE can reﬂect this prior knowledge, and give greater
Fig. 2. The deﬁnition of asthma varies across disciplines of public health. Although each of these deﬁnitions is accurate within a narrow context, they can cause confusion as
they are not comprehensive to all stakeholders and do not describe the full range of characteristics that deﬁne ‘‘asthma’’. It is important to clearly deﬁne what is meant by the
term ‘‘asthma’’, as well as other key terms, when developing a hazard characterization tool.
Table 2
A list of terms related to asthma that are not clearly or consistently deﬁned and may lead to confusion in the evaluation and hazard identiﬁcation of exposures that may cause
asthma.
Term Reasons why a harmonized and/or clariﬁed deﬁnition is needed
Irritant-induced asthma (IIA) This term is often used to describe non-sensitizing causes of asthma (e.g., RADS). However, there may be multiple
modes of action for non-immunologically based asthma. An alternative deﬁnition might be the development of
asthma via mechanisms other than allergic sensitization
Reactive airways dysfunction syndrome (RADS) This term does not ﬁt the classic deﬁnition of asthma, which includes chronic inﬂammation. It is instead an irritant-
induced syndrome caused by a single heavy irritant inhalation exposure. Additionally, RADS may not result in
chronic disease and lung remodeling
Asthma induction This term is often used to identify the initial sensitizing phase of asthma but can be misconstrued to represent the
trigger, or induction, of an asthma attack
Asthma elicitation This term often is used to describe the events that lead to the onset of asthma symptoms in a person with pre-
existing asthma
Asthma trigger This term is non-speciﬁc, but implies exacerbation of pre-existing disease following exposure to another stressor
(that may not be chemical in nature)
Asthmagen This term is overly vague and cannot capture whether an exposure causes new-onset asthma or triggers an
asthmatic response in a person with pre-existing asthma. When used, the reader should closely consider the context
Respiratory sensitizer The term respiratory sensitizer is ambiguous and implies that a substance is only acting via the respiratory tract.
Some dermal exposures may also lead to sensitization of the respiratory tract
Asthmagenic potential This term indicates the potential to induce asthma by any mechanism, but this is not very informative. As with the
term ‘‘asthmagen’’, it is not clear whether this refers to the potential for inducing asthma or triggering pre-existing
disease
Table 3
Assessment of common features from weight-of-evidence frameworks for evaluating asthma.
WoE
approach?a
Varying levels of certainty
about causality?b
Hierarchy of
evidencec
All lines of
evidenced
Hazard for asthma
inductione
Hazard for asthma
elicitationf
Mixtures
consideredg
AOEC (2008) Yes No Yes No Yes No No
TERA (2014) Yes Yes Yes Yes Yes Yes No
WHO/IPCS (IPCS 2012) Yes Yes Yes Yes Yes Yes No
Selgrade et al. 2012 Yes No Yes Yes No No Yes
EU HSE/GHS (2007) Yes Yes Yes Yes Yes No Yes
a Does the framework use a WoE approach?
b Does the framework allow the investigator to assign a level of certainty to their toxicological conclusions about causality, based on pre-determined categories?
c Does the framework clearly state how to prioritize evidence (e.g., should human evidence be weighed more heavily than animal)?
d Does the framework include all lines of evidence (i.e., in vivo, in vitro, in silico) in its approach?
e Does the framework provide guidance for identifying exposures that may induce asthma?
f Does the framework provide guidance for identifying exposures that may elicit an asthmatic response?
g Does the framework provide guidance for evaluating mixtures and/or multiple exposures?
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Table 4
A comparison of the designations that can be assigned following use of weight-of-evidence frameworks from multiple organizations.
New-Onset Asthmaa Asthma Exacerbationb Asthma (Unspec.)c Skin Sensitizationd Respiratory Sensitizatione Irritationf
AOEC (2008) Yes No – No Yes Yes
TERA (2014) No No Yes Yes Yes Yes
WHO/IPCS (IPCS 2012) Yes Yes Yes Yes Yes No
Selgrade et al. 2012 No No No Yes Yes No
EU HSE/GHS (2007) Yes No – Yes Yes Yes
a Does the framework provide guidance for determining if an exposure causes new-onset asthma?
b Does the framework provide guidance for determining if an exposure exacerbates pre-existing asthma?
c Does the framework provide guidance for determining if an exposure is related to asthma, but does not differentiate between induction and exacerbation?
d Does the framework provide guidance for determining if an exposure causes skin sensitization?
e Does the framework provide guidance for determining if an exposure causes respiratory sensitization?
f Does the framework provide guidance for determining if an exposure causes irritation (skin or respiratory)?
Table 5
Summary of the Advantages and Disadvantages of Frameworks for Determining Relationships of a Chemical Exposure with Asthma.
Organization Advantages Disadvantages
AOEC (2008)  Uses a WoE approach to determine the cause(s) of asthma induction (i.e.,
one positive response is not enough to determine causality)
 Focuses on new-onset cases of asthma
 Mostly limited to occupational exposures
 Does not consider animal data in its approach
TERA (2014)  Considers multiple lines of evidence
 The framework is based on assessing asthma, not just asthma-related
surrogates
 Attempts to identify the cause of new-onset asthma
 Uses skin sensitization and irritation data in the absence of respiratory
information which allows for assessment of a wider array of exposures
 Allows investigators to make characterizations based on multiple levels
of certainty
 Use of dermal sensitization and irritation data may lead to
false associations, but is ultimately a conservative approach
 Does not include structural-activity information
WHO/IPCS (IPCS 2012)  Clearly deﬁnes an approach for determining respiratory and dermal sen-
sitization and allergy, including prioritization of data types and tests
 Allows the user to deﬁne their level of conﬁdence in determining causal-
ity of immunotoxic exposures
 Does not provide a framework for assessing asthma, just the
surrogate responses related to sensitization
Selgrade et al. (2012)  Clearly deﬁnes an approach for determining dermal sensitization, includ-
ing prioritization of data types and tests
 Clearly deﬁnes the strength of evidence for human data
 Use of animal data, structural activity relationships and other evidence
(e.g., in vitro data) for a WoE
 Does not provide a framework for assessing asthma, just the
surrogates
EU HSE/GHS (2007)  Has minimum recommendations for epidemiological data quality
 Clearly deﬁnes an approach for determining respiratory sensitization,
including prioritization of data types and tests
 Does not provide a framework for assessing asthma, just the
surrogates such as sensitization
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MOA. However, heterogeneity of the many biological mechanisms
(Fig. 1) increases the difﬁculty of identifying key events in the MOA
and limits validation of a single predictive test or test battery for
asthma. The end result is a heavy reliance on the WoE approach
using diverse data inputs for hazard characterization.
The application of WoE approaches to consumer product expo-
sures and asthma is often heavily subjective,may not be transparent
(i.e., decision rules are not clear), andmayyield verydifferent results
depending on the organization and/or individual doing the assess-
ment. To address these limitations, more formalized and systematic
approaches for determining WoE (e.g., hypothesis-based weight of
evidence methods) are gaining popularity for communicating
uncertainties or gaps in the available data and organizing and eval-
uating information (Linkov et al., 2009; Rhomberg et al., 2013).
One particular complication in applying the WoE approach for
asthma hazard characterization is the need tomake decisions when
faced with uncertainty regarding the predictive power of the types
of evidence (assays) that are most commonly available. The use of
dermal sensitization assays is one complication for predicting the
potential for sensitization of the respiratory tract. Although some
skin sensitizers have been shown to also cause respiratory sensiti-
zation (Arts et al., 2008) and the induction phase of allergy is gen-
erally similar for both types of allergic response (Arts and Kuper,
2007), this is not true for all low molecular weight sensitizers or
high molecular weight sensitizers or allergens that cannot pass
through the skin (Andersson et al., 2011). Identiﬁcation of irritantpotential for prediction of asthma faces similar data challenges as
for sensitization. These include evaluating multiple complex mech-
anisms, extrapolation across routes and test species, and interpret-
ing human response data (Doty et al., 2004; Dalton, 2001). Due to
these complications, signiﬁcant assay development for evaluation
of relationships between chemical exposures and asthma is ongo-
ing using metrics such as genomics (Vandebriel and van Loveren,
2010), fractional nitric oxide in exhaled breath (Dweik et al.,
2011; Barath et al., 2013; Donohue and Jain, 2013), ovalbumin chal-
lenge models (Caceres et al., 2009), and bronchoalveolar lavage
(BAL) ﬂuid evaluation and peptide release, as well as neurokinins
of inﬂammatory release, and contractility of the airways in preci-
sion cut lung slices (Sanderson, 2011; Switalla et al., 2010).
A systematic process to decide which of the various laboratory
animal models/assays to use in supporting conclusions about
asthma hazard characterization systems should be employed.
Some key considerations in rating the utility of an assay include:
(1) recognition by a consensus body as predictive of asthma; (2)
empirical validation of the model/assay; (3) direct or indirect mea-
sure of respiratory sensitization or irritation; (4) evaluation of
responses in the model or assay that are speciﬁc to asthma, respi-
ration sensitization, or irritation; (5) inclusion of multiple
measures (to test internal consistency); and (6) direct assessment
of functional responses or their precursors. Developing a weighted
score applied to each assay, in the context of asthma, can
standardize a WoE approach and make documentation more trans-
parent. Instead of scoring individual tests, it may be more useful to
Fig. 3. A brief overview of hazard characterization for asthma and chemical
exposures, which considers the relevance of the exposure scenario, toxicity mode of
action (MOA), and weight of evidence (WoE).
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they provide, and then weigh how the results by assay category
provide information in the broader context of asthma.
Although theWoE approaches employed for decisions regarding
asthma have not yet been harmonized, opportunities for better
alignment of WoE techniques include increased use of MOA and
quantitative tools for evidence-baseddecisionmaking. For example:
 Current systems often rely on ‘‘lines of evidence’’ deﬁned by a
hierarchical approach with inferred relevance to human
responses organized by assay system type (in vivo is better than
in vitro, which is better than in silico). Each assay should be con-
sidered relative to its predictivity. However, many of these
assays do not have speciﬁcity or sensitivity information speciﬁc
to asthma, so predictivity may be impossible to ascertain.
 Organization of families of assays along mode of action lines
may be more informative than other categorization systems.
Such an approach recognizes that conclusions about the pri-
mary cause of a clinical response will likely reﬂect an integra-
tion of multiple assays that test different aspects of the same
MOA pathway. Use of mode of action principles also aids in
deﬁning the scope of the asthma assessment (e.g., immunologic
versus non-immunological; new-onset versus response
elicitation).
 Current systems often rely on qualitative considerations to sup-
port a conclusion. Such decision-making would be strengthened
with access to assay validation data (e.g., predictivity measures
and data on sensitivity and selectivity) and decision support
systems that begin to provide rules that allow for reproducible
WoE decisions. Even with such systems, clear documentation of
the rationale for decisions would be required.
5. Conclusion
The analysis of hazard characterization methods in this manu-
script provides a guide for the assessment of potential asthma haz-
ards associated with exposures to chemicals present in consumer
products. Placing existing methods in the context of their intended
uses and documenting their inherent strengths and limitationsprovides the input to support decision-making and decreases the
potential for misinterpretation of the outputs of existing hazard
classiﬁcation schemes. The analysis also serves as a base for the
development of new user-speciﬁc hazard and risk characterization
approaches that integrate elements of various existing systems to
meet the needs of speciﬁc safety assessment applications. This
work is intended as one step in the ongoing goal to develop
improved methods for proactive assessment strategies for con-
sumer exposure scenarios.Conﬂict of interest
Beckett has nothing to disclose.
Patterson reports contractual support to TERA for workshop and
manuscript preparation from the American Cleaning Institute
on behalf of a collaboration of trade associations. During the
conduct of the study and reports, TERA has received funding
for related work related investigating asthma potential from
exposure to consumer products, from American Cleaning Insti-
tute, outside the submitted work.
Dalton reports personal fees from Public Health Forum, during
the conduct of the study.
Gadagbui reports that TERA has received contractual support to
TERA for workshop and manuscript preparation from the Amer-
ican Cleaning Institute on behalf of a collaboration of trade
associations, during the conduct of the study, and reports that
TERA has received funding for related work related investigat-
ing asthma potential from exposure to consumer products from
the American Cleaning Institute, outside the submitted work.
Kimber has nothing to disclose.
Maier reports personal fees and contractual support to TERA for
workshop and manuscript preparation from the American
Cleaning Institute on behalf of a collaboration of trade associa-
tions, during the conduct of the study, and reports that TERA
has received funding for related work related investigating
asthma potential from exposure to consumer products from
American Cleaning Institute, outside the submitted work.
Vincent reports contractual support to TERA for workshop and
manuscript preparation from the American Cleaning Institute
on behalf of a collaboration of trade associations, during the
conduct of the study, and reports that TERA has received fund-
ing for related work related investigating asthma potential from
exposure to consumer products from the American Cleaning
Institute, outside the submitted work.
Selgrade reports personal fees from Toxicology Excellence for
Risk Assessment (TERA), during the conduct of the study; per-
sonal fees from ICF International, personal fees from National
Toxicology Program, personal fees from TERA, grants from U.S.
EPA, outside the submitted work.Acknowledgments
The manuscript was developed based on inputs and delibera-
tions of a peer consultation process attended by the authors and
facilitated by the 501(c)3 organization Toxicology Excellence for
Risk Assessment. This work was funded by a collaboration of con-
sumer product and chemical trade associations that include the
following organizations: American Chemistry Council, American
Cleaning Institute, American Petroleum Institute, Chemical Produc-
ers and Distributors Association, Consumer Specialty Products
Association, CropLife America, Personal Care Products Council,
SOCMA (Society of Chemical Manufacturers and Afﬁliates, Grocery
Manufacturers Association, Research Institute for Fragrance Mate-
rials, and Styrene Information and Research Center.
A. Maier et al. / Regulatory Toxicology and Pharmacology 70 (2014) 37–45 45ReferencesACI (American Cleaning Institute), 2012. Industry Sponsored Asthma Science
Forum: Report of Workshop held May 10, 2011. <www.cleaninginstitute.org/
assests/1/Page/AsthmaScienceForumReport.pdf>.
Andersson, S.E. et al., 2011. The LLNA: A brief review of recent advances and
limitations. J. Allergy. 2011, 10. http://dx.doi.org/10.1155/2011/424203 (Article
ID 424203).
AOEC, 2008. Revised Protocol: Criteria for Designating Substances as Occupational
Asthmagens on the AOEC List of Exposure Codes.
Arts, J.H.E., Kuper, C.F., 2007. Animal models to test respiratory allergy of low
molecular weight chemicals: a guidance. Methods 41, 61–71.
Arts, J.H.E., de Jong, W.H., van Triel, J.J., Schijf, M.A., de Klerk, A., van Loveren, H.,
Kuper, C.F., 2008. The respiratory local lymph node assay as a tool to study
respiratory sensitizers. Toxicol. Sci. 106 (2), 423–434.
ATS (American Thoracic Society), 2010. Asthma, In: Schraufnagel, D.E., (Ed.),
Breathing in America: Diseases, Progress, and Hope. <http://www.thoracic.org/
education/breathing-in-america/resources/chapter-3-asthma.pdf>.
Barath, S., Mills, N.L., Adelroth, E., Olin, A.-C., Blomber, A., 2013. Diesel exhaust but
not ozone increases fraction of exhaled nitric oxide in a randomized controlled
experimental exposure study of healthy human subjects. Environ. Health 12, 36.
Baur, X., Bakehe, P., Vellguth, H., 2012. Bronchial asthma and COPD due to irritants
in the workplace – an evidence-based approach. J. Occup. Med. Toxicol. 7, 19.
Bergeron, C., Hamid, Q., 2005. Relationship between asthma and rhinitis:
epidemiologic, pathophysiologic, and therapeutic aspects. Allergy Asthma
Clin. Immunol. 1 (2), 81–87.
Bernstein, J.A., 1993. Reactive Airways Dysfunction Syndrome (RADS). DPICtions
(12, pp. 1–3).
Bernstein, I.L., Chan-Yeung, M., Malo, J.-C., Bernstein, D.I., 2006. Asthma in the
Workplace, 3rd ed. Taylor & Francis Group, LLC, New York, NY.
BTS (British Thoracic Society), 2009. British Guideline on the Management of
Asthma: A National Clinical Guideline. <http://www.brit-thoracic.org.uk/
Portals/0/Guidelines/AsthmaGuidelines/
sign101%20revised%20June%2009.pdf>.
Caceres, A.I., Brackmann, M., Elia, M.D., et al., 2009. A sensory neuronal ion channel
essential for airway inﬂammation and hyperreactivity in asthma. PNAS 106
(22), 9099–9104.
Centers for Disease Control and Prevention. Work Related Asthma 38 States and
District of Columbia, 2006–2009. MMWR/May 25, 2012/Vol. 61/No. 20.
Dalton, P., 2001. Evaluating the human response to sensory irritation: implications
for setting occupational exposure limits. AIHAJ 62 (6), 723–729.
Donohue, J.F., Jain, N., 2013. Exhaled nitric oxide to predict corticosteroid
responsiveness and reduce asthma exacerbation rates. Resp Med. 107 (7),
943–952.
Doty, R.L., Cometto-Muniz, J.E., Jalowayski, A.A., Dalton, P., Kendal-Reed, M.,
Hodgson, M., 2004. Assessment of upper respiratory tract and ocular irritative
effects of volatile chemicals in humans. Crit. Rev. Toxicol. 34 (2), 85–142.
Dweik, R.A. et al., 2011. An ofﬁcial ATS clinical practice guideline: interpretation of
exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit.
Care Med. 184, 602–615.
EU (European Union), 2013. Major and Chronic Diseases: Asthma. Available from:
<http://ec.europa.eu/health/major_chronic_diseases/diseases/asthma/
index_en.htm>.
Hunting, McDonald, 1995. Development of a hierarchical exposure coding system
for clinic-based surveillance of occupational disease and injury. Appl. Occup.
Environ. Hyg. 10.
IPCS, 2012. Guidance for immunotoxicity risk assessment for chemicals.
Harmonization Project Document No. 10. World Health Organization.
Jaakkola, J.J.K., Jaakkola, M.S., 2006. Professional cleaning and asthma. Curr. Opin.
Allergy Clin. Immunol. 6, 85–90.Kimber, I., Dearman, R.J., 2002. Chemical respiratory allergy: role of IgE antibody
and relevance of route of exposure. Toxicology 27 (181–182), 311–315.
Lemanske, R.F., Busse, W.W., 2010. Asthma: clinical expression and molecular
mechanisms. J. Allergy Clin. Immunol. 125 (2 S2), S95–S102.
Linkov, I., Loney, D., Cormier, S., Satterstrom, F.K., Bridges, T., 2009. Weight-of-
evidence evaluation in environmental assessment: review of qualitative and
quantitative approaches. Sci. Total Environ. 407 (19), 5199–5205.
Mapp, C.E. et al., 1994. Mechanisms and pathology of occupational asthma. Eur.
Respir. J. 7, 544–554.
Mapp, C.E., Boschetto, P., Maestrelli, P., Fabbri, L.M., 2005. Occupational asthma. Am.
J. Respir. Crit. Care Med. 172, 280–305.
Mayo Clinic, 2012. Asthma. Available from: <http://www.mayoclinic.com/health/
asthma/DS00021>.
NHLBI (National Heart, Lung, and Blood Institute), 2007. Expert Panel Report 3:
Guidelines for the Diagnosis and Management of Asthma. National Asthma
Education and Prevention Program. U.S. Department of Health and Human
Services. National Institutes of Health. <http://www.nhlbi.nih.gov/guidelines/
asthma/asthgdln.pdf>.
Nielsen, G.D. et al., 2007. Do indoor chemicals promote development of airway
allergy? Indoor Air 17, 236–255.
NIH (National Institutes of Health), 2012. Healthy Environments: A compilation of
substances linked to asthma. Prepared by Perkins+Will for the NIH Division of
Environmental Protection.
NLM (National Library of Medicine), 2013. A.D.A.M. Medical Encyclopedia: Asthma.
PubMed Health. Available from: <http://www.ncbi.nlm.nih.gov/pubmedhealth/
PMH0001196/>.
Quirce, S., Barranco, P., 2010. Cleaning agents and asthma. J. Investig. Allergol. Clin.
Immunol. 20 (7), 542–550.
Rhomberg, L.R., Goodman, J.E., Bailey, L.A., et al., 2013. A survey of frameworks for
best practices in weight-of-evidence analyses. Crit. Rev. Toxicol. 43 (9), 753–
784.
Rosenman, K. et al., 2003. Cleaning products and work-related asthma. JOEM 2003
(45), 556–563.
Sanderson, M.J., 2011. Exploring lung physiology in health and disease with lung
slices. Pulm. Pharm. Ther. 24, 452–465.
Selgrade et al., 2006. Inconsistencies between cytokine proﬁles, antibody responses,
and respiratory hyperresponsiveness following dermal exposure to isocyanates.
Toxicol. Sci. 94 (1), 1080117.
Selgrade, M.K. et al., 2012. Decision trees for evaluating skin and respiratory
sensitizing potential of chemicals in accordance with European regulations.
Regul. Toxicol. Pharm. 63, 371–380.
Switalla, S., Knebel, J., Ritter, D., Krug, N., Braun, A., Sewald, K., 2010. Effects of acute
in vitro exposure of murine precision-cut lung slices to gaseous nitrogen dioxide
and ozone in an air-liquid interface (ALI) culture. Toxicol. Lett. 196, 117–124.
TERA (Toxicology Excellence for Risk Assessment), 2014. Characterizing Potential
Chemical Asthma Hazards: A Weight of Evidence Method and Case Study for
Acetic Acid. Available from: <http://www.tera.org/ART/
ACI%20WoE%20White%20Paper%206-2-14.pdf>.
US EPA (United States Environmental Protection Agency), 2010. The Cost of Illness
Handbook. Chapter IV.2: Cost of Asthma. Available from: <http://www.epa.gov/
opptintr/coi/pubs/iv_2.pdf>.
Vandebriel, R.J., van Loveren, H., 2010. Non-animal sensitization testing: state-of-
the-art. Crit. Rev. Toxicol. 40, 389–404.
Walker, C. et al., 1992. Allergic and non-allergic asthmatics have distinct patterns of
T-cell activation and cytokine production in peripheral blood and
bronchoalveolar lavage. Am. Rev. Respir. Dis. 146, 109–115.
WHO (World Health Organization), 2013. Asthma: Deﬁnition. Available from:
<http://www.who.int/respiratory/asthma/deﬁnition/en/>.
Zock, J.P., 2005. World at work: cleaners. Occup. Environ. Med. 62, 581–584.
Zock, J.P., Vizcaya, D., Le Moual, N., 2010. Update on asthma and cleaners. Curr.
Opin. Allergy Clin. Immunol. 10 (2), 114–120.
